Dr. Reddy’s Laboratories has announced the launch of Obeda® tablets, an oral semaglutide therapy for patients with diabetes in India. The launch marks another major step in the company’s expansion of its GLP-1 portfolio after recently introducing semaglutide injections in India and Canada.
Oral semaglutide is considered an important advancement in diabetes management because it offers patients a convenient non-injectable treatment option. Experts believe that easier administration may encourage earlier treatment initiation, improve patient adherence, and help lower the risk of long-term diabetes-related complications.
According to the company, the newly launched Obeda® tablets are designed to provide greater flexibility and treatment choice for people living with chronic metabolic diseases. The product has been developed and formulated in-house, allowing the company to focus on maintaining reliable supply and consistent quality standards for patients across India.
Speaking on the launch, M. V. Ramana said that every diabetes patient has unique treatment needs, and expanding the GLP-1 portfolio will help improve access to advanced diabetes care. He also emphasized the company’s focus on innovation, affordability, and delivering better long-term outcomes for patients suffering from chronic metabolic disorders.
The launch comes at a time when demand for GLP-1 therapies is increasing rapidly worldwide due to their growing role in diabetes and obesity management. With Obeda® tablets, Dr. Reddy’s aims to strengthen its position in the fast-growing metabolic disease treatment segment in India.
